PCVX

Vaxcyte, Inc. NASDAQ

Healthcare ·Biotechnology ·US · vaxcyte.com

$58.49

Mkt Cap $8.4B

52w Low $28.09 82.4% of range 52w High $65.00

50d MA $58.70 200d MA $46.18

P/E (TTM) -10.1x

EV/EBITDA -8.5x

P/B 2.9x

Debt/Equity 0.1x

ROE -28.5%

P/FCF -9.4x

RSI (14) —

ATR (14) —

Beta 1.39

50d MA $58.70

200d MA $46.18

Avg Volume 1.4M

About

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strai…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 24, 2026	AMC	-1.53	-1.80	-17.7%	61.35	-5.8%	+2.8%	-2.2%	+0.6%	+1.0%	-2.5%	—
Nov 4, 2025	AMC	-1.27	-1.56	-22.8%	41.35	-1.0%	-2.5%	+0.9%	+0.7%	+3.8%	+10.4%	—
Aug 6, 2025	AMC	-1.12	-1.22	-8.9%	33.00	-8.9%	-9.1%	-9.4%	-10.1%	-9.1%	-4.4%	—
May 7, 2025	AMC	-1.02	-1.04	-2.0%	29.00	+4.5%	+8.4%	+7.4%	+8.9%	+3.6%	+1.4%	—
Feb 25, 2025	AMC	-1.16	-1.02	+12.1%	79.35	+4.5%	-0.9%	-6.5%	-8.0%	-9.1%	-11.5%	—
Nov 5, 2024	AMC	-1.10	-0.83	+24.5%	107.56	+6.5%	-3.2%	-4.5%	-0.8%	-3.6%	-7.6%	—
Aug 6, 2024	AMC	-0.98	-1.10	-12.8%	73.93	-0.2%	-4.6%	-0.4%	+5.4%	+5.6%	+4.5%	—
May 8, 2024	AMC	-1.13	-0.85	+24.8%	66.79	-2.7%	-1.8%	-2.4%	-1.6%	+0.8%	+7.2%	—
Feb 27, 2024	AMC	-0.90	-1.82	-102.2%	81.05	-3.0%	-7.3%	-8.9%	-11.5%	-11.7%	-11.8%	—
Nov 6, 2023	AMC	-0.79	-0.91	-15.2%	48.25	-0.5%	+4.1%	+4.9%	-0.4%	-0.2%	+0.4%	—
Aug 8, 2023	AMC	-0.67	-0.70	-4.5%	48.87	-1.8%	-3.9%	-2.9%	-3.4%	-5.9%	-2.8%	—
May 8, 2023	AMC	-0.80	-0.70	+12.5%	50.89	+2.9%	+4.8%	+2.8%	-1.7%	-2.8%	-1.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 26	BTIG	Maintains	Buy → Buy	—	$63.04	$61.67	-2.2%	-4.8%	-2.1%	-1.7%	-5.1%	-4.6%
Feb 2	Guggenheim	Maintains	Buy → Buy	—	$53.57	$53.25	-0.6%	+7.1%	+4.0%	+3.2%	+0.6%	+4.8%
Nov 10	BTIG	Maintains	Buy → Buy	—	$41.65	$42.01	+0.9%	+3.0%	+9.6%	+10.7%	+9.4%	+16.9%
Oct 16	BTIG	Maintains	Buy → Buy	—	$43.94	$43.86	-0.2%	-0.8%	-3.5%	-2.4%	-3.6%	-3.3%
Apr 8	Needham	Maintains	Buy → Buy	—	$32.51	$33.05	+1.7%	-7.1%	-5.3%	-13.7%	-4.0%	-1.4%
Apr 1	BofA Securities	Maintains	Buy → Buy	—	$37.76	$37.12	-1.7%	-14.6%	-10.8%	-19.1%	-16.3%	-13.9%
Apr 1	Needham	Maintains	Buy → Buy	—	$37.76	$37.12	-1.7%	-14.6%	-10.8%	-19.1%	-16.3%	-13.9%
Apr 1	Goldman Sachs	Maintains	Buy → Buy	—	$37.76	$37.12	-1.7%	-14.6%	-10.8%	-19.1%	-16.3%	-13.9%
Mar 12	Guggenheim	Maintains	Buy → Buy	—	$69.85	$70.00	+0.2%	+4.9%	+4.5%	+6.5%	+7.7%	+7.0%
Feb 26	Guggenheim	Maintains	Buy → Buy	—	$79.35	$82.92	+4.5%	-0.9%	-6.5%	-8.0%	-9.1%	-11.5%
Feb 26	Needham	Maintains	Buy → Buy	—	$79.35	$82.92	+4.5%	-0.9%	-6.5%	-8.0%	-9.1%	-11.5%
Feb 24	BTIG	Maintains	Buy → Buy	—	$79.74	$79.78	+0.1%	+2.4%	-0.5%	-1.4%	-6.9%	-8.4%
Feb 11	Needham	Maintains	Buy → Buy	—	$85.94	$84.53	-1.6%	-0.9%	-0.6%	-2.4%	-2.3%	-4.0%
Dec 24	BTIG	Maintains	Buy → Buy	—	$87.08	$87.05	-0.0%	-1.3%	-1.5%	-7.0%	-5.8%	-6.0%
Nov 6	Needham	Maintains	Buy → Buy	—	$107.56	$114.58	+6.5%	-3.2%	-4.5%	-0.8%	-3.6%	-7.6%
Sep 10	Mizuho	Maintains	Outperform → Outperform	—	$115.28	$116.50	+1.1%	+0.8%	-1.5%	-1.0%	+0.6%	-0.9%
Sep 4	BofA Securities	Maintains	Buy → Buy	—	$110.15	$113.05	+2.6%	-0.9%	+1.8%	+1.3%	+4.7%	+5.5%
Sep 3	Needham	Maintains	Buy → Buy	—	$80.76	$107.67	+33.3%	+36.4%	+35.2%	+38.8%	+38.2%	+42.7%
Sep 3	BTIG	Maintains	Buy → Buy	—	$80.76	$107.67	+33.3%	+36.4%	+35.2%	+38.8%	+38.2%	+42.7%
Sep 3	Jefferies	Maintains	Buy → Buy	—	$80.76	$107.67	+33.3%	+36.4%	+35.2%	+38.8%	+38.2%	+42.7%
Sep 3	Leerink Partners	Maintains	Outperform → Outperform	—	$80.76	$107.67	+33.3%	+36.4%	+35.2%	+38.8%	+38.2%	+42.7%
Aug 7	Needham	Maintains	Buy → Buy	—	$73.93	$73.78	-0.2%	-4.6%	-0.4%	+5.4%	+5.6%	+4.5%
Aug 7	BTIG	Maintains	Buy → Buy	—	$73.93	$73.78	-0.2%	-4.6%	-0.4%	+5.4%	+5.6%	+4.5%
Jun 28	Needham	Maintains	Buy → Buy	—	$78.77	$78.83	+0.1%	-4.1%	-2.3%	-3.4%	-3.2%	-1.2%
May 9	Needham	Maintains	Buy → Buy	—	$66.79	$65.00	-2.7%	-1.8%	-2.4%	-1.6%	+0.8%	+7.2%
Apr 10	Needham	Maintains	Buy → Buy	—	$64.51	$62.74	-2.7%	-3.1%	+0.5%	-4.1%	-3.3%	-3.5%
Mar 12	Mizuho	Maintains	Buy → Buy	—	$70.25	$71.52	+1.8%	+2.0%	+4.3%	-1.4%	-0.8%	-3.1%
Feb 28	Needham	Maintains	Buy → Buy	—	$81.05	$78.65	-3.0%	-7.3%	-8.9%	-11.5%	-11.7%	-11.8%
Jan 2	BofA Securities	Maintains	Buy → Buy	—	$62.80	$62.01	-1.3%	+0.2%	-0.5%	+2.5%	-4.8%	-3.3%
Nov 7	Needham	Maintains	Buy → Buy	—	$48.25	$48.00	-0.5%	+4.1%	+4.9%	-0.4%	-0.2%	+0.4%
Aug 22	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$49.71	$49.61	-0.2%	-0.6%	+0.6%	-0.7%	+1.2%	+3.3%
Aug 9	Needham	Maintains	Buy → Buy	—	$48.87	$48.00	-1.8%	-3.9%	-2.9%	-3.4%	-5.9%	-2.8%
May 9	Needham	Maintains	Buy → Buy	—	$50.89	$52.39	+2.9%	+4.8%	+2.8%	-1.7%	-2.8%	-1.0%
Apr 18	BofA Securities	Maintains	Buy → Buy	—	$42.34	$43.52	+2.8%	+4.2%	+8.1%	+7.2%	+6.6%	+2.5%
Apr 18	TD Cowen	Maintains	Outperform → Outperform	—	$42.34	$43.52	+2.8%	+4.2%	+8.1%	+7.2%	+6.6%	+2.5%
Mar 1	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$40.97	$41.24	+0.7%	+1.7%	+1.3%	+3.8%	+0.7%	-0.3%
Feb 28	Needham	Maintains	Buy → Buy	—	$42.30	$40.00	-5.4%	-3.1%	-1.5%	-1.9%	+0.6%	-2.5%
Feb 28	Guggenheim	Maintains	Buy → Buy	—	$42.30	$40.00	-5.4%	-3.1%	-1.5%	-1.9%	+0.6%	-2.5%
Jan 3	Needham	Maintains	Buy → Buy	—	$47.95	$48.82	+1.8%	-1.6%	-2.3%	-3.9%	-2.7%	-4.2%
Dec 16	SVB Leerink	Maintains	Outperform → Outperform	—	$45.48	$45.36	-0.3%	+0.7%	-5.7%	-1.2%	+2.2%	+4.8%
Dec 15	Guggenheim	Maintains	Buy → Buy	—	$45.72	$46.12	+0.9%	-0.5%	+0.2%	-6.2%	-1.7%	+1.7%
Nov 17	BTIG	Maintains	Buy → Buy	—	$43.35	$43.33	-0.0%	-0.2%	+1.6%	+3.0%	+1.9%	+1.9%
Nov 8	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$43.35	$43.87	+1.2%	+3.3%	-0.1%	+3.3%	+2.5%	+1.6%
Jul 7	Needham	Maintains	Buy → Buy	—	$29.38	$28.88	-1.7%	-2.1%	+1.2%	-0.1%	+0.7%	-0.6%
Jul 7	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$29.38	$28.88	-1.7%	-2.1%	+1.2%	-0.1%	+0.7%	-0.6%

Recent Filings

8-K

Vaxcyte, Inc. -- 8-K Filing

Vaxcyte secured manufacturing capacity through Lonza's completed facility and North Carolina fill-finish expansion, positioning the company to commercialize pneumococcal vaccines with $2.4 billion in cash plus $600.2 million from a February 2026 equity offering.

Feb 24

8-K

Vaxcyte, Inc. -- 8-K Filing

Vaxcyte (PCVX) launched an at-the-market offering through Nasdaq with a placement agent receiving up to 3.0% compensation, allowing the company flexible capital raising at current market prices.

Feb 24

8-K

Vaxcyte, Inc. -- 8-K Filing

Vaxcyte completed an underwritten public offering, establishing customary legal protections and indemnification obligations between the company and underwriters for the securities transaction.

Feb 2

Data updated apr 26, 2026 7:01pm · Source: massive.com